BioMarin closes $4.8B Amicus acquisition, adds rare‑disease drugs Galafold and Pombiliti

BioMarin has finalized its $4.8 billion acquisition of Amicus Therapeutics, expanding its portfolio with new treatments for rare genetic conditions and a promising late-stage drug candidate. This strategic move consolidates specialized therapies under one pharmaceutical entity.

BioMarin Pharmaceutical Inc. completed its acquisition of Amicus Therapeutics, a strategic transaction in the rare-disease sector. Rare diseases affect a small percentage of the population and often require highly specialized treatments. This deal positions BioMarin to broaden its offerings in this specific market.

The acquisition valued Amicus Therapeutics at approximately $4.8 billion, with BioMarin paying $14.50 per share in cash. BioMarin financed this all-cash deal through a combination of debt and existing capital. Funding included a new $2.0 billion Term Loan B and an $800 million Term Loan A. A Term Loan B is a syndicated bank loan typically used for acquisitions, while a Term Loan A has shorter maturities and amortization schedules. BioMarin also secured a $600 million revolving credit facility, which provides flexible borrowing similar to a credit card for businesses. Existing 5.5% senior notes due in 2034 and cash on hand supplemented these new debt facilities.

The acquisition significantly enhances BioMarin's drug pipeline. It adds Galafold, a medication for Fabry disease, a genetic disorder affecting multiple organs, and Pombiliti with Opfolda, treatments for Pompe disease, another rare genetic condition causing muscle weakness. Additionally, BioMarin gains U.S. rights to DMX-200, a Phase 3 candidate for focal segmental glomerulosclerosis, a severe kidney disease.

This transaction immediately strengthens BioMarin's standing in the rare-disease therapeutic area by integrating established treatments and a late-stage asset. The expanded portfolio presents new revenue streams and leverages BioMarin's existing expertise in developing and commercializing specialized therapies. The substantial debt financing reflects a calculated investment into growth within a high-value market segment. Investors will now monitor how this combined portfolio impacts BioMarin's financial performance and market strategy. Future communications regarding updated financial guidance will provide more insight into the long-term implications of this acquisition.